We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Significant mitral regurgitation as a predictor of long-term prognosis in patients receiving cardiac resynchronisation therapy.
Kardiologia Polska 2018
BACKGROUND: Cardiac resynchronisation therapy (CRT) has been shown to reduce functional mitral regurgitation, although the relationship between significant mitral regurgitation (SMR) and the clinical prognosis of CRT remains uncertain.
AIM: We sought to investigate the association of baseline SMR with long-term outcomes in patients undergoing CRT.
METHODS: A total of 296 consecutive patients undergoing CRT were enrolled. SMR was quantified by colour Doppler in all patients at baseline and defined as level ≥ 3 on the severity scale. The primary endpoints included all-cause death, heart failure hospitalisation (HFH), and heart transplantation, and the secondary endpoints were response to CRT and New York Heart Association (NYHA) class III or IV six months after CRT implantation.
RESULTS: The mean age was 59 ± 11 years, and 202 (68.2%) patients were male. Among all patients, 124 (41.9%) presented with baseline SMR. Over a mean follow-up of 4.17 ± 3.16 years, there were 53 (17.9%) cases of all-cause death, 41 (13.8%) cases of HFH, and four (1.4%) cases of heart transplantation. SMR was positively associated with primary endpoint events (hazard ratio [HR] 1.602, 95% confidence interval [CI] 1.083-2.371, p = 0.019), HFH (HR 3.567, 95% CI 1.763-7.219, p < 0.001) and NYHA class III or IV (HR 2.101, 95% CI 1.313-3.363, p = 0.002). After adjusting for multiple factors, we found that SMR (HR 1.785, 95% CI 1.091-2.920, p = 0.021), ischaemic heart disease (HR 1.628, 95% CI 1.062-2.494, p = 0.025), and the lack of use of spironolactone (HR 2.044, 95% CI 1.040-4.017, p = 0.038) were independent predictors of primary endpoints, and SMR remained an independent predictor of HFH (HR 4.622, 95% CI 1.955-10.923, p < 0.001).
CONCLUSIONS: Significant mitral regurgitation before CRT implantation was strongly associated with long-term poor progno-sis. SMR was positively associated with HFH rather than all-cause death and CRT response.
AIM: We sought to investigate the association of baseline SMR with long-term outcomes in patients undergoing CRT.
METHODS: A total of 296 consecutive patients undergoing CRT were enrolled. SMR was quantified by colour Doppler in all patients at baseline and defined as level ≥ 3 on the severity scale. The primary endpoints included all-cause death, heart failure hospitalisation (HFH), and heart transplantation, and the secondary endpoints were response to CRT and New York Heart Association (NYHA) class III or IV six months after CRT implantation.
RESULTS: The mean age was 59 ± 11 years, and 202 (68.2%) patients were male. Among all patients, 124 (41.9%) presented with baseline SMR. Over a mean follow-up of 4.17 ± 3.16 years, there were 53 (17.9%) cases of all-cause death, 41 (13.8%) cases of HFH, and four (1.4%) cases of heart transplantation. SMR was positively associated with primary endpoint events (hazard ratio [HR] 1.602, 95% confidence interval [CI] 1.083-2.371, p = 0.019), HFH (HR 3.567, 95% CI 1.763-7.219, p < 0.001) and NYHA class III or IV (HR 2.101, 95% CI 1.313-3.363, p = 0.002). After adjusting for multiple factors, we found that SMR (HR 1.785, 95% CI 1.091-2.920, p = 0.021), ischaemic heart disease (HR 1.628, 95% CI 1.062-2.494, p = 0.025), and the lack of use of spironolactone (HR 2.044, 95% CI 1.040-4.017, p = 0.038) were independent predictors of primary endpoints, and SMR remained an independent predictor of HFH (HR 4.622, 95% CI 1.955-10.923, p < 0.001).
CONCLUSIONS: Significant mitral regurgitation before CRT implantation was strongly associated with long-term poor progno-sis. SMR was positively associated with HFH rather than all-cause death and CRT response.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app